1-7 of 7
Eduard Cmunt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era

Tomas Hornak, Jiri Mayer, Petra Cicatkova, Lukas Semerad, Anezka Kvetkova, Hana Klamova, Edgar Faber, Petra Belohlavkova, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Dana Srbova, Hana Zizkova, Lucia Vrablova, Ivana Skoumalova, Jaroslava Voglova, Tereza Jurkova, Marika Chrapava, Tomas Jurcek, Ivana Jeziskova, Marie Jarosova, Katerina Machova Polakova, Tomas Papajik, Pavel Zak, Pavel Jindra, Daniela Zackova
Journal: Blood
Blood (2023) 142 (Supplement 1): 3166.
https://doi.org/10.1182/blood-2023-174455
Published: 2023
Journal Articles

Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission

Daniela Žácková, Edgar Faber, Lukáš Stejskal, Michal Karas, Petra Bělohlávková, Hana Klamová, Olga Černá, Eduard Cmunt, Petra Čičátková, Lukáš Semerád, Tomáš Horňák, Anežka Kvetková, Jiřina Procházková, Jitka Rychlíčková, Radka Štěpánová, Adam Svobodník, Kateřina Machová Poláková, Ivana Ježíšková, Tomáš Jurček, Marek Borský, Ondřej Wiewiorka, Regina Demlová, Jiří Mayer
Journal: Blood
Blood (2021) 138 (Supplement 1): 3606.
https://doi.org/10.1182/blood-2021-146221
Published: 2021
Journal Articles

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Eva Koriťáková, RNDr., PhD, Michael Doubek, MD PhD, Edgar Faber, MD PhD, Daniela Žáčková, MD PhD, Jan M. Horáček, MD PhD, Petra Bělohlávková, MD PhD, Eduard Cmunt, MD PhD, František Folber, MD PhD, Pavel Jindra, MD PhD, Hana Klamová, MD PhD, Zdeněk Kořístek, MD PhD, Lukáš Stejskal, MD, Tomáš Szotkowski, MD PhD, Cyril Šálek, MD PhD, Renata Kellnerová, MD PhD, Marika Chrápavá, Mgr.
Journal: Blood
Blood (2019) 134 (Supplement_1): 5905.
https://doi.org/10.1182/blood-2019-126395
Published: 2019
Journal Articles

Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group

Lukas Smolej, MDPhD, Yvona Brychtova, MD PhD, Michael Doubek, Prof., MD PhD, Eduard Cmunt, MDPhD, Martin Spacek, MD, PhD, David Belada, MD, Monika Motyckova, MDPhD, Irena Zygulova, MD, Dagmar Adamova, MD, Vit Prochazka, MDPhD, Martin Simkovic, MD, Katerina Klaskova, MS, Tomas Kozak, MDPhD
Journal: Blood
Blood (2014) 124 (21): 4670.
https://doi.org/10.1182/blood.V124.21.4670.4670
Published: 2014
Journal Articles

Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL)

Petra Obrtlikova, MD, Anna Jonasova, MD, Magda Siskova, MD, Eduard Cmunt, MD, Adela Berkova, MD, Josef Karban, MD, Katerina Svackova, Marek Trneny, MD
Journal: Blood
Blood (2012) 120 (21): 1790.
https://doi.org/10.1182/blood.V120.21.1790.1790
Published: 2012
Journal Articles

Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group

Lukas Smolej, M.D., Ph.D., Martin Spacek, M.D., Yvona Brychtova, MD, David Belada, M.D., Ph.D., Jiri Schwarz, M.D., Ph.D., Michael Doubek, MD, PhD, Monika Motyckova, M.D., Eduard Cmunt, M.D., Ph.D., Peter Rohon, MD, Katerina Klaskova, M.S., Tomas Kozak, M.D., Ph.D.
Journal: Blood
Blood (2010) 116 (21): 2466.
https://doi.org/10.1182/blood.V116.21.2466.2466
Published: 2010
Journal Articles

The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–2009.

Hana Klamova, Daniela Zackova, Edgar Faber, MD, PhD, Katerina Steinerova, Michal Karas, Eva Demeckova, Jaroslava Voglova, MD, Ludmila Demitrovicova, Elena Tothova, Juraj Chudej, MD, Imrich Markuljak, Tomas Kozak, Eduard Cmunt, M.D., Ph.D., Marie Jarosova, Katerina Machova-Polakova, Kyra Michalova, PhD, DSc, Ladislav Dusek, Jan Muzik, Martin Mistrik, Jiri Mayer, MD, PhD, Marek Trneny, MD, PhD, Karel Indrak, MD., PhD.
Journal: Blood
Blood (2010) 116 (21): 1239.
https://doi.org/10.1182/blood.V116.21.1239.1239
Published: 2010